Q1FY27 saw robust revenue and EBITDA growth, led by semaglutide launches and biologics momentum. Capacity expansion is on track, with a second cartridge line set for Q2 and a reaffirmed FY28 revenue outlook of $400m. EBITDA margin and customer base continue to strengthen.Original document: OneSourc…
Q1 FY 2027 saw 37% revenue and 39% EBITDA growth, driven by semaglutide launches, new contracts, and strong biologics momentum. Capacity expansions in DDC, injectables, and softgel support robust FY 2028 guidance, with further growth expected beyond as new markets open.Based on OneSource Specialty…
Revenue and profitability improved significantly year-over-year, with consolidated profit after tax reaching Rs. 249.97 million and strong standalone results. Exceptional items included legal charges and employee settlements, while a major legal dispute remains ongoing.Original document: OneSource…
Onesource Specialty Pharma Ltd NSE:ONESOURCE:
